Navigation Links
Perle BioScience Selects BlazeFund As Its Crowd Funding Platform
Date:9/4/2013

BOSTON, Sept. 4, 2013 /PRNewswire/ -- BlazeFund, a new equity crowd funding company in Boston, Massachusetts, has listed the first biotech company on their platform. Atlanta-based Perle BioScience is a life sciences company whose mission is to address patient needs that have been considered "impossible" to tackle.

(Logo: http://photos.prnewswire.com/prnh/20130808/CG60459LOGO)

Perle BioScience's founder, Dr. Claresa Levetan, is internationally recognized as a leader of diabetes research. She previously co-founded CureDM and was a lead inventor of a therapeutic drug for the reversal of diabetes. CureDM's IP portfolio was licensed to Sanofi in 2010 for upfront and commercial milestone payments of a potential value totaling $335M.

Dr. Levetan is raising capital for Perle BioScience to "pave the way for a revolutionary therapeutic treatment which will create a transformational shift in the treatment of diabetes," states Dr. Levetan. According to the American Diabetes Association, there are currently 26 million diabetes patients in the US.

Dr. Levetan indicates, "Nearly 1 out of 10 healthcare dollars or 4 out of 10 Medicare dollars are spent on patients with diabetes. As health care costs are spiraling and the diabetes population is growing, Perle BioScience is looking to address the underlying mechanisms that cause diabetes. Our treatment will be a huge benefit to society as a whole – not just for diabetic patients - but also in terms of managing healthcare costs."

Perle BioScience elected to utilize equity crowd funding to obtain the company's growth capital. Dr. Levetan mentions, "Perle is making a paradigm shift in the treatment of diabetes, and we specifically chose equity crowd funding, which is a perfect fit, since it is creating a paradigm shift as it relates to accessing capital. The ability to expose our company's technology to so many types of investors, from small to large, is invaluable. More importantly, we specifically selected BlazeFund based on their healthcare/ life science focus and the experience of their leadership team."

Aaron Sanders, CEO of BlazeFund, adds, "BlazeFund provides the entire investment community with exposure and access to innovative ventures. We are very proud and enthusiastic to be working with an industry leader that has the caliber of Perle BioScience."

For more information about BlazeFund please contact:
Aaron Sanders, CEO & Founder
aaron@blazefund.com


'/>"/>
SOURCE BlazeFund
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. 150,000 Medical Professionals Stay Paperless with Practice Fusion
2. Wacoms New DTU-1031 Provides Paperless Electronic Signature Solution for Businesses
3. Whats New with Flu this Season: Industry Recommendations, New Vaccines and 100% Paperless Flu Program Solution
4. Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
5. Neurocrine Biosciences Announces the Start of Second Phase III Study of Elagolix in Endometriosis
6. PuraMed BioScience Invited to Discuss LipiGesic M on Armed Forces Network
7. Genocea Biosciences Selected To Present Late-Breaking Oral Presentation At ICAAC 2013
8. Regado Biosciences, Inc. Announces Closing of Initial Public Offering
9. Sangamo BioSciences to Acquire Ceregene
10. PuraMed BioScience Sponsors Miles for Migraine Race with LipiGesic M
11. Regado Biosciences, Inc. Announces Pricing of Initial Public Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Any dentist who has made ... the current process. Many of them do not even offer ... difficulties and high laboratory costs involved. And those who ARE ... at such a high cost that the majority of today,s ... Dr. Parsa Zadeh , founder of Dental Evolutions Inc. ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a Media ... give their videos a whole new perspective by using the title layers in ... Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women ... diagnosed with endometriosis. These women need a treatment plan to not only alleviate ... that can help for preservation of fertility and ultimately achieving a pregnancy. The ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
Breaking Medicine News(10 mins):